Literature DB >> 2023898

Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.

M N Teng1, B H Park, H K Koeppen, K J Tracey, B M Fendly, H Schreiber.   

Abstract

The relationship between detrimental (cachectic) and beneficial (antitumor) effects of tumor necrosis factor (TNF) was studied in mice bearing murine tumors transfected to secrete human TNF. In vitro, the TNF-producing transfectants were resistant to the secreted TNF and grew at rates similar to those of untransfected cells or transfected cells that did not secrete TNF. However, tumors formed by the TNF-secreting cells in vivo remained much smaller than the nonsecreting (transfected and untransfected) tumors. This inhibition of tumor growth required only relatively low serum levels of TNF, persisted for many weeks, and was independent of T cells since it occurred in nude mice. Growth of the TNF-secreting tumors increased dramatically after treatment with anti-human TNF antibody, indicating that extracellular TNF secreted by the tumor cells was necessary for the tumor inhibition. Severe weight loss characteristic of cachexia only occurred in animals with very high serum TNF levels (250 pg/ml) and could be prevented or reversed by anti-TNF antibody treatment. These data are consistent with the existence of a therapeutic window in which persistent exposure to human TNF can lead to prolonged inhibition of tumor growth in the absence of T-cell immunity or severe weight loss and without development of resistant tumor variants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023898      PMCID: PMC51486          DOI: 10.1073/pnas.88.9.3535

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

Authors:  P L Felgner; T R Gadek; M Holm; R Roman; H W Chan; M Wenz; J P Northrop; G M Ringold; M Danielsen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes.

Authors:  T S Bringman; B B Aggarwal
Journal:  Hybridoma       Date:  1987-10

3.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

Review 4.  Endogenous cachectin/tumour necrosis factor-alpha production contributes to experimental cancer-associated cachexia.

Authors:  L L Moldawer; B Sherry; S F Lowry; A Cerami
Journal:  Cancer Surv       Date:  1989

5.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

7.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

8.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.

Authors:  E A Havell; W Fiers; R J North
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

9.  Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.

Authors:  H J Stauss; C Van Waes; M A Fink; B Starr; H Schreiber
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma.

Authors:  R J North; E A Havell
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  21 in total

Review 1.  Keratinocyte-derived tumor necrosis factor and the physiopathology of the skin.

Authors:  P F Piguet
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Gene therapy in pediatric oncology.

Authors:  E Benaim; B P Sorrentino
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha.

Authors:  J Theys; S Nuyts; W Landuyt; L Van Mellaert; C Dillen; M Böhringer; P Dürre; P Lambin; J Anné
Journal:  Appl Environ Microbiol       Date:  1999-10       Impact factor: 4.792

Review 4.  Strategies for cancer gene therapy using adenoviral vectors.

Authors:  V Descamps; M T Duffour; M C Mathieu; N Fernandez; L Cordier; M A Abina; E Kremer; M Perricaudet; H Haddada
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

5.  In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.

Authors:  T Ohira; Y Ohe; Y Heike; E R Podack; K J Olsen; K Nishio; M Nishio; Y Miyahara; Y Funayama; H Ogasawara
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

Authors:  H Hock; M Dorsch; U Kunzendorf; Z Qin; T Diamantstein; T Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 8.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 9.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

10.  In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.

Authors:  S E Karp; P Hwu; A Farber; N P Restifo; M Kriegler; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1992-09-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.